BC Extra | Nov 9, 2012
Financial News

Cardioxyl raises $28.1M in B round

Cardioxyl Pharmaceuticals Inc. (Chapel Hill, N.C.) raised $28.1 million in a series B round led by new investor Orbimed Advisors. New investor Osage University and existing investors New Enterprise Associates and Aurora Funds also participated....
BC Week In Review | Aug 30, 2010
Clinical News

CXL-1020: Phase IIa started

Cardioxyl began a double-blind, placebo-controlled, international Phase IIa trial to evaluate intravenous CXL-1020 in 54-66 patients. Cardioxyl Pharmaceuticals Inc. , Chapel Hill, N.C.   Product: CXL-1020   Business: Cardiovascular   Molecular target: Not available   Description:...
BC Week In Review | Aug 9, 2010
Clinical News

CXL-1020: Phase I/IIa data

In a double-blind, placebo-controlled, dose-escalating, U.S. Phase I/IIa trial in 28 patients with chronic stable heart failure, IV CXL-1020 was well tolerated up to 10 µg/kg/minute with no serious adverse events. CXL-1020 also displayed significant...
BC Extra | Aug 3, 2010
Financial News

Cardioxyl raises $15 million

Cardioxyl Pharmaceuticals Inc. (Chapel Hill, N.C.) raised $15 million in an extension of a series A round. Existing investors Aurora Funds and New Enterprise Associates co-led the round. Cardioxyl also said its lead compound, CXL-1020...
BC Week In Review | Oct 12, 2009
Company News

Cardioxyl, Evotec deal

Evotec received an undisclosed milestone payment from Cardioxyl under an earlier deal for Evotec to provide its medicinal chemistry services to support the development of a Cardioxyl compound for heart failure. The payment was triggered...
BC Week In Review | Sep 28, 2009
Clinical News

Cardioxyl preclinical data

In canine models of heart failure, CXL-1020 improved left ventricular systolic and diastolic function. The small molecule nitroxyl (HNO) donor also reduced venous load without altering heart rate in normal and failing hearts. Data were...
BC Week In Review | Jul 13, 2009
Clinical News

CXL-1020: Phase I/IIa started

Last month, Cardioxyl began a dose-escalation, U.S. Phase I/IIa trial to evaluate intravenous CXL-1020 in up to 36 patients with chronic stable heart failure. Cardioxyl Pharmaceuticals Inc. , Towson, Md.   Product: CXL-1020   Business: Cardiovascular...
Items per page:
1 - 7 of 7